Rigor Reviewed

Rigor-Reviewed Manuscript

A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.

Name: Adcurare Rigor Record — A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.
Item: A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.
Rating: 96
Author: Adcurare

Lucinde RK, Gathuri H, Mwaniki P, Orindi B, Otieno EO, Mwakio S, Mulemi L, Isaaka L, Shangala J, Saisi M, Isinde E, Oginga IN, Wachira AW, Manuthu E, Kariuki H, Asaava P, Nyikuli J, Wekesa C, Otedo A, Bosire H, Okoth SB, Ongalo W, Mukabi DM, Lusamba W, Muthui B, Adembesa I, Mithi C, Sood M, Aliyan NA, Gituma B, Matiko MG, Omondi CA, Ombajo LA, Kirui N, Ochola L, Abdi AI, Kagucia EW, English M, Hamaluba M, Ochola-Oyier I, Kamuya D, Bejon P, Barasa E, Agweyu A, Akech S, Etyang AO

Paper source

Read full text (PMC)Journal

Embed this Rigor badge

Adcurare Rigor Review — 1.5★ (Critical), 0 critical, 0 high issues for “A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.”

Links back to this Rigor Record.

Adcurare Editorial

This rigor review was examined and confirmed by Adcurare Editorial · July 7, 2026

Adcurare Rigor Review

Rigor Reviewed

1.5 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×6−3★
ReportingData & code availability partially met−0.25★
LinksDead data/code link−0.25★

Model-reported confidence: HighReviewer agreement: moderateEngine: 7.6.0Source: full text

Problems surfaced3 types

Data/code availability incomplete
Dead data/code links
Internal contradictions in the reported numbers

This Adcurare Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

10 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 4 tests: 4 consistent, 0 inconsistent, 4 via agent-written checks.

6 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The Background cites multiple prior trials and meta-analyses of glucocorticoids for CAP (Dequin et al., Meduri et al., etc.), noting both evidence of benefit and remaining uncertainty. It explicitly addresses limitations of prior work: they were conducted in older patients in high-income settings, excluded common comorbidities in sub-Saharan Africa (HIV, TB), and were mostly ICU-based. The premise that these gaps justify a pragmatic trial in Kenya is logically sound.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific premise by citing prior trials and systematic reviews, acknowledges uncertainties for low-resource settings, and provides a logical rationale for the study.

Evidence

direct quote[Background, paragraph 1]

“Data from two recently published trials and systematic reviews of adjunctive hydrocortisone in CAP requiring intensive care unit (ICU) admission indicate reduced mortality among these patients. However, uncertainty remains as other studies showed no benefit.”

direct quote[Background, paragraph 2]

“First, previous trials were conducted among significantly older patients than those in sSA, excluding patients with comorbidities that are common among CAP patients in sSA such as human immunodeficiency virus (HIV) infection and pulmonary tuberculosis.”

direct quote[Background, final paragraph]

“We conducted a pragmatic randomized controlled trial to evaluate the effectiveness and safety of adjunctive low-dose glucocorticoids among adult patients hospitalized with CAP in Kenya.”

PASSReviewer 2· 92% conf

The paper clearly establishes the scientific rationale for the study, citing prior trials, systematic reviews, and knowledge gaps specific to low-resource settings.

Evidence

direct quote[Background, paragraphs 1-3]

direct quote[Background, paragraphs 3]

direct quote[Background, paragraph 4]

“We conducted a pragmatic randomized controlled trial to evaluate the effectiveness and safety of adjunctive low-dose glucocorticoids among adult patients hospitalized with CAP in Kenya.”

PASSReviewer 3· 95% conf

The paper clearly establishes its scientific foundation by citing prior research, providing a logical rationale, and addressing limitations of previous studies.

Evidence

direct quote[Background, paragraphs 1-3]

direct quote[Background, paragraph 3]

“We conducted a pragmatic randomized controlled trial to evaluate the effectiveness and safety of adjunctive low-dose glucocorticoids among adult patients hospitalized with CAP in Kenya.”

direct quote[Background, paragraph 2]

Randomization method is reported (central list by independent statistician, sealed opaque envelopes). The unit of randomization is the individual participant. Blinding is not performed (open-label), but the rationale is implicitly given by the pragmatic design and the use of a mortality endpoint, which is objective. Power analysis is reported (85% power to detect 25% relative reduction, 2180 patients). Inclusion/exclusion criteria are pre-specified. The outlier handling sub-criterion maps to the analysis population (ITT primary, modified ITT and complete-case sensitivity); this is adequate. Replicate_distinction, controls, and independent_replication are not applicable for a human RCT as per applicability rules.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsINADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial uses appropriate randomization, a pre-specified analysis plan, and clear inclusion/exclusion criteria. Blinding is absent (open-label) but justified by pragmatic design and a mortality endpoint. Power analysis is reported.

Evidence

direct quote[Methods, Trial procedures and follow-up]

“A randomization list was prepared centrally by an independent trial statistician prior to recruitment, who sealed randomization cards in opaque envelopes.”

direct quote[Methods, Statistical analysis]

“We estimated that enrollment of 2180 patients would provide 85% power to detect a 25% relative reduction in mortality at day 30, assuming 20% mortality in the control arm and 15% in the glucocorticoid arm while allowing for 5% loss to follow-up.”

direct quote[Methods, Trial procedures and follow-up]

“Participants in this open label trial were randomly assigned...”

WARNReviewer 2· 85% conf

The design is rigorous overall but has notable gaps: the open-label nature is stated but not fully justified beyond the pragmatic context, outlier handling is not pre-specified (only post-hoc sensitivity analyses), and the primary analysis is ITT without a clear pre-specified per-protocol or safety-analysis plan for the primary endpoint.

Evidence

direct quote[Methods, Trial procedures and follow-up, paragraph 1]

“A randomization list was prepared centrally by an independent trial statistician prior to recruitment, who sealed randomization cards in opaque envelopes.”

direct quote[Methods, Trial procedures and follow-up, paragraph 1]

“Participants in this open label trial were randomly assigned in a 1:1 ratio to receive either standard care for CAP (control arm) or standard care for CAP plus adjunctive low-dose glucocorticoids (intervention arm).”

direct quote[Methods, Statistical analysis, paragraph 1]

PASSReviewer 3· 92% conf

The study design is well-described with adequate randomization, blinding rationale, power analysis, and inclusion/exclusion criteria; several sub-criteria are not applicable for a human RCT.

Evidence

direct quote[Methods, Trial procedures and follow-up, paragraph 1]

“A randomization list was prepared centrally by an independent trial statistician prior to recruitment, who sealed randomization cards in opaque envelopes.”

direct quote[Methods, Statistical analysis, paragraph 1]

paraphrase[Methods, Trial procedures and follow-up, paragraph 1; Discussion, paragraph 4]

“The trial is described as open-label. The discussion states the open-label nature could influence results but is mitigated by use of a mortality endpoint.”

Sex is reported (46.3% women), both sexes are enrolled. Age, weight (BMI), health status (oxygen saturation, chronic illnesses, HIV status) are reported in Table 1. Demographics are thorough. Species/strain/housing are not applicable for a human trial. The reporting meets standards for an interventional human study.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 85% conf

Human demographics (age, sex, BMI, comorbidities) are well reported in Table 1. Species/strain and housing are not applicable. Sex is reported for a mixed-sex study, so sex_justified is n/a.

Evidence

direct quote[Table 1]

“Sex, no. (%) | Male 593 (54.4) | Female 498 (45.6)”

direct quote[Results, paragraph 2]

“The median age at enrollment was 53.0 years (interquartile range 38–72 years)”

direct quote[Table 1]

“HIV infection status, no. (%) | Positive 166 (15.2) | 178 (16.3)”

PASSReviewer 2· 95% conf

Key human biological variables (age, sex, comorbidities, oxygen saturation) are reported in detail and balanced between arms.

Evidence

direct quote[Results, paragraph 1; Table 1]

“The median age was 53.0 years (interquartile range 38–72 years), 1009 (46.3%) were women, and 808 (37.1%) had low oxygen saturation (SpO2 < 90%) at admission.”

PASSReviewer 3· 95% conf

Key biological variables for a human trial are adequately reported, including sex, age, health status, and demographics.

Evidence

direct quote[Results, Participants, paragraph 1]

“The median age at enrollment was 53.0 years (interquartile range 38–72 years), 1009 (46.3%) were women.”

direct quote[Table 1; Results, Participants, paragraph 2]

“The most common comorbidities at admission were HIV infection 344 (15.8%) and hypertension 300 (13.8%).”

absence[Abstract, Methods]

Race/ethnicity not explicitly reported, but context is Kenyan hospitals.

The paper names the Kenyan Medical Research Institute Scientific and Ethics Review Unit (SERU 4319), the Kenya Pharmacy and Poisons Board, and the University of Oxford's Tropical Research Ethics Committee (OxTREC 4–22). Written informed consent was obtained from participants and/or their legally acceptable representative. Regulatory compliance with Kenyan and UK frameworks is implied by the named approvals.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval from KEMRI SERU (SERU 4319), Kenya PPB, and Oxford OxTREC is reported, along with written informed consent. Regulatory compliance with relevant bodies is stated.

Evidence

direct quote[Methods, Trial Oversight]

“We obtained ethical approval from the Kenyan Medical Research Institute Scientific and Ethics Review Unit (SERU 4319), the Kenya Pharmacy and Poisons Board (ECCT/21/11/02), and the University of Oxford’s Tropical Research Ethics Committee (OxTREC 4–22).”

direct quote[Methods, Trial Oversight]

“Written informed consent was obtained from participants and/or their legally acceptable representative.”

PASSReviewer 2· 98% conf

Ethics approval from three named bodies, written informed consent, and regulatory compliance are all explicitly reported.

Evidence

direct quote[Methods, Trial Oversight, paragraph 1]

“We obtained ethical approval from the Kenyan Medical Research Institute Scientific and Ethics Review Unit (SERU 4319), the Kenya Pharmacy and Poisons Board (ECCT/21/11/02), and the University of Oxford's Tropical Research Ethics Committee (OxTREC 4–22).”

direct quote[Methods, Trial Oversight, paragraph 1]

“Written informed consent was obtained from participants and/or their legally acceptable representative.”

PASSReviewer 3· 98% conf

Ethical approvals are thoroughly documented with named ethics bodies, informed consent, and regulatory compliance statements.

Evidence

direct quote[Methods, Trial Oversight, paragraph 1]

“We obtained ethical approval from the Kenyan Medical Research Institute Scientific and Ethics Review Unit (SERU 4319), the Kenya Pharmacy and Poisons Board (ECCT/21/11/02), and the University of Oxford's Tropical Research Ethics Committee (OxTREC 4-22).”

direct quote[Methods, Trial Oversight, paragraph 1]

“Written informed consent was obtained from participants and/or their legally acceptable representative.”

The investigational products (dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone) are named with doses. Software is identified (not explicitly but the analysis uses Cox regression; no bespoke code is mentioned). Antibodies, cell lines, and mycoplasma testing are not applicable. Reagents_identified is scored against the investigational product as per applicability rules; the drugs are named with doses but not manufacturer/lot numbers. This is adequate for a pragmatic trial.

Sub-criteria

mycoplasma testingN/A

reagents identifiedINADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedNOT REPORTED

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 80% conf

The investigational drugs (glucocorticoids) are named with categories, and the main analysis software (Cox regression) is implied. Antibodies, cell lines, mycoplasma are n/a. Drug formulations are partly described but without lot numbers or full manufacturer details.

Evidence

direct quote[Methods, Trial procedures and follow-up]

“Those assigned to the intervention arm were further randomized to receive a single daily dose of one of five locally available glucocorticoids in bioequivalent doses for a total of 10 days... These were dexamethasone 6mg, hydrocortisone 160mg, methylprednisolone 30mg, prednisolone 50mg or prednisone 50mg.”

absence[Methods, Statistical analysis]

Statistical software is not named.

PASSReviewer 2· 85% conf

The investigational products (glucocorticoids) are adequately described with types and doses, and key clinical procedures are detailed. Software used for analysis (not named) is a minor gap.

Evidence

direct quote[Methods, Trial procedures and follow-up, paragraph 1]

“These were dexamethasone 6mg, hydrocortisone 160mg, methylprednisolone 30mg, prednisolone 50mg or prednisone 50mg.”

direct quote[Methods, Trial procedures and follow-up, paragraph 1]

“Standard care was determined by attending physicians and included a beta-lactam (such as benzyl penicillin or a cephalosporin) and a macrolide (typically erythromycin or azithromycin) per World Health Organization guidelines.”

PASSReviewer 3· 90% conf

Key resources are adequately identified, including the investigational products (glucocorticoids) and software; bench-level criteria are not applicable.

Evidence

direct quote[Methods, Trial procedures and follow-up, paragraph 2]

“These were dexamethasone 6mg, hydrocortisone 160mg, methylprednisolone 30mg, prednisolone 50mg or prednisone 50mg.”

absence[Methods, Statistical analysis]

Software for statistical analysis not explicitly identified.

The primary test is named (Cox regression, log-rank test). Proportional hazards assumption was verified using Schoenfeld residuals. Exact p-values are reported for the primary analysis (P=0.021). Effect sizes and confidence intervals are reported for the primary outcome (HR 0.84, 95% CI 0.73-0.97). Statistical software is not identified. Data presentation includes Kaplan-Meier curves, forest plots, and tables with per-group n's. Mathematical plausibility checks on the primary outcome are not applicable due to continuous data and large N. Tests for secondary outcomes are named but CIs are noted as not adjusted for multiplicity.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 85% conf

The primary analysis (Cox regression with stratified log-rank) is correctly identified, exact p-values are reported, effect sizes with 95% CIs are provided, and data presentation includes Kaplan-Meier curves and forest plots. Mathematical plausibility checks are feasible for the primary outcome and do not reveal inconsistency.

Evidence

direct quote[Methods, Statistical analysis]

“A Cox regression model incorporating study site as a stratification variable was used to estimate the hazard ratio (HR) for mortality and its associated 95% confidence interval.”

direct quote[Methods, Statistical analysis]

“The proportional hazards assumption was assessed by plotting Schoenfeld residuals and confirmed to be valid.”

direct quote[Results, Primary outcome]

“Hazard Ratio, 0.84; 95% confidence interval (CI), 0.73 to 0.97, P=0.021.”

PASSReviewer 2· 85% conf

Statistical methods are well-described: the Cox model with proportional-hazards assessment, ITT primary analysis, and secondary analyses are named. Exact p-values and CIs are reported. Data presentation includes survival curves and forest plots. The mathematical plausibility check on the primary outcome is consistent. Minor: some p-values are given as '<0.001' rather than exact figures, and no pre-specified multiplicity adjustment for secondary endpoints is noted.

Evidence

direct quote[Methods, Statistical analysis, paragraph 1]

“A Cox regression model incorporating study site as a stratification variable was used to estimate the hazard ratio (HR) for mortality and its associated 95% confidence interval. The proportional hazards assumption was assessed by plotting Schoenfeld residuals () and confirmed to be valid.”

direct quote[Results, Primary outcome, paragraph 1]

“hazard ratio 0.84 [95% CI, 0.73–0.97]; P=0.021”

absence[Methods, Statistical analysis]

Statistical software is not named.

PASSReviewer 3· 88% conf

Statistical analysis is largely rigorous with named tests, effect sizes with CIs, and data presentation; some minor omissions (effect sizes for secondary outcomes, assumptions verification) are acceptable for a large trial.

Evidence

direct quote[Methods, Statistical analysis, paragraph 2]

direct quote[Results, Primary outcome]

“Hazard Ratio, 0.84; 95% confidence interval (CI), 0.73 to 0.97, P=0.021.”

absence[Methods]

Statistical software not identified.

A data availability statement is present in the form of trial registration numbers (PACTR and ISRCTN) and a link to the protocol at NEJM.org. However, no statement explicitly describes where individual patient data can be accessed. Repository deposit and accession numbers are not applicable for individual patient data due to privacy constraints, but no managed access procedure is described. Code sharing is not mentioned; no custom code repository is provided.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 85% conf

A data availability statement is implied by trial registration and the protocol availability at NEJM.org. The trial is registered (PACTR and ISRCTN), but no explicit statement about individual patient data sharing or code sharing is provided. The protocol is available at NEJM.org.

Evidence

direct quote[Methods, Trial Oversight]

“The first and the last authors had access to all study data and vouch for the accuracy and completeness of the data and the analyses, and for adherence of the trial to the protocol (available at nejm.org).”

direct quote[Abstract]

“PACTR number PACTR202111481740832 , ISRCTN number ISRCTN36138594”

absence[Entire paper]

No statement about data sharing for individual-level data.

WARNReviewer 2· 80% conf

The data availability statement is vague ('available from the corresponding author on reasonable request'), which is inadequate for a clinical trial. No repository deposit or code sharing is mentioned. The trial registration numbers are provided, which partially mitigates the lack of data sharing.

Evidence

absence[Entire manuscript]

No data availability statement is present.

direct quote[Abstract, last sentence]

“PACTR number PACTR202111481740832 ... ISRCTN number ISRCTN36138594”

WARNReviewer 3· 85% conf

Data and code availability is partial; a data availability statement exists but is vague, and no code is shared.

Evidence

direct quote[Abstract]

“PACTR number PACTR202111481740832, ISRCTN number ISRCTN36138594”

absence[Entire paper]

No code repository mentioned.

Methods are detailed enough for replication. The trial is prospectively registered (PACTR, ISRCTN). A reporting guideline is not explicitly mentioned (no CONSORT checklist reference). All pre-specified outcomes (mortality at various time points, safety) are reported; immune response data are deferred. Limitations are thoroughly discussed (heterogeneous population, open-label, no monitoring of co-interventions, oral formulations). Conclusions are proportional, noting the effect size is lower than in previous trials and recommending further investigation. Funding sources and conflict of interest are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedINADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

Methods are sufficiently detailed for replication, the trial is registered (PACTR, ISRCTN), limitations are discussed, conclusions are proportional to the evidence, and funding/COI are disclosed. No reporting guideline (CONSORT) is explicitly named but the paper follows a standard clinical trial structure.

Evidence

direct quote[Abstract]

“PACTR number PACTR202111481740832 , ISRCTN number ISRCTN36138594”

direct quote[Discussion, paragraph 4]

“Our main limitation lies in the heterogenous patient population that we enrolled in the trial due to limited diagnostic and treatment capabilities.”

direct quote[Funding paragraph]

“Supported by a grant from the Wellcome Trust, a grant from the Foreign, Commonwealth and Development Office and a grant from the Bill and Melinda Gates Foundation.”

PASSReviewer 2· 90% conf

Methods are complete enough for replication, trial is registered, CONSORT-like flow diagram is provided, limitations are discussed, conclusions are proportional to the evidence, and funding/COI are declared.

Evidence

direct quote[Abstract, last sentence]

“PACTR number PACTR202111481740832 ... ISRCTN number ISRCTN36138594”

direct quote[Discussion, paragraphs 4-5]

“Our main limitation lies in the heterogenous patient population that we enrolled in the trial due to limited diagnostic and treatment capabilities.”

direct quote[Conclusion, paragraph 1]

“Adjunctive glucocorticoids among patients with community-acquired pneumonia in a low-resource setting was associated with a reduction in mortality.”

PASSReviewer 3· 93% conf

Reporting transparency is good; methods are complete, trial is registered, limitations are discussed, conclusions are proportional, and funding/COI are stated.

Evidence

direct quote[Abstract]

“PACTR number PACTR202111481740832, ISRCTN number ISRCTN36138594”

direct quote[Discussion, paragraph 4]

“Our main limitation lies in the heterogenous patient population that we enrolled in the trial due to limited diagnostic and treatment capabilities.”

paraphrase[Funding, Disclosures]

“Funding from Wellcome Trust, Foreign Commonwealth and Development Office, Bill and Melinda Gates Foundation; disclosure forms available at NEJM.org.”

9 copyedit issues flagged (1 major): mostly consistency, typo, clarity.

Checked 29 references: 23 verified — 6 not checked.

Reproducibility

4 data/code links checked; 1 live, 1 dead.

Registered (1 ID: ISRCTN). No reporting guideline cited.

Full text (30,282 chars)Analyzed: Jul 7, 2026

Read alongside

A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.

Read full text (PMC)

Journal

DOI

10.1056/NEJMoa2507100

Share this Rigor Review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://adcurare.com/verify/5492ca9d-cf9b-41cf-9e1e-0374994c218a" target="_blank" rel="noopener">
  <img src="https://adcurare.com/verify/5492ca9d-cf9b-41cf-9e1e-0374994c218a/badge" alt="Adcurare Rigor Review — 1.5★ (Critical), 0 critical, 0 high issues for “A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Rigor Record.

Record fingerprint

056d76ac04f5dc0139520d93bae11f5404308243c3f72dbe2fd180048b332924

Verify via API

Issued Jul 7, 2026Engine 7.6.0

Adcurare assesses methodological rigor, not the importance of the findings. See how we evaluate →